PTK7 and hematologic disorder: One of the most recent developments was the design of CAR-specific binding aptamers (CAR-ap) (Fig. 6B) that successfully combine for the first time the specificity of aptamers with the potency of immune effectors to selectively target PTK7 in the context of hematological malignancies (Table 1) [87].